WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for potentially first-in-class targeted oncology therapies, today …
TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) announced today its financial results for the three months and nine months ended September 30, 2020 (“Q3 2020”). Q3 2020 Highlights Portfolio continues to perform …
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary …
LITTLE ROCK, ARKANSAS, USA, November 13, 2020 /EINPresswire.com/ -- The Arkansas US Navy Veterans Mesothelioma Advocate says, "We are appealing to the wife or adult son-daughter of a Navy Veteran with recently diagnosed mesothelioma anywhere in …
The "Comida Casera," home-cooking, of Texas Mexican American families, has been appropriated by commercial cultural poachers. HOUSTON, TX, US, November 13, 2020 /EINPresswire.com/ -- The comida casera, home-cooking, of Texas Mexican American …
Sensyne Health appoints President, North America, to lead US expansion Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Derek Baird …
TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of November. The distribution will be payable on December 7, 2020 to unitholders of …
All amounts in U.S. dollars unless otherwise stated TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Onex Corporation (TSX: ONEX) today announced its financial results for the third-quarter and nine-months ended September 30, 2020 and an update on matters …
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today …
Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indications First-in-class TDP-43 therapeutic and diagnostic programs advance as the target’s role in a newly …
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics (“the Company”), a global research company and subsidiary of …
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat …
GREENWICH, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, has been named to the 2021 FreightTech 25 as one of the transportation industry’s most technologically disruptive …
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno- …
TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three months ended September 30, 2020. As previously disclosed, all financial figures are now reported in US …
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London …
Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases Completed rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and …
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of PR006 for Frontotemporal Dementia with GRN Mutations …
Waterloo, Canada, Nov. 13, 2020 (GLOBE NEWSWIRE) -- The Centre for International Governance Innovation (CIGI) and Gateway House: Indian Council on Global Relations will welcome Canada and India’s top diplomats on Tuesday to discuss the growing strategic …
PRINCETON, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular …
